Wogonin and Related Natural Flavones Overcome Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Protein Resistance of Tumors by Down-regulation of C-FLIP Protein and Up-regulation of TRAIL Receptor 2 Expression

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2011 Nov 17

PMID 22086925

Citations 42

Authors

Jie Ding

Gernot Polier

Rebecca Kohler

Marco Giaisi

Peter H Krammer

Min Li-Weber

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent that kills various tumor cells without damaging normal tissues. However, many cancers remain resistant to TRAIL. To overcome TRAIL resistance, combination therapies using sensitizers of the TRAIL pathway would be an efficacious approach. To investigate potential sensitizers of TRAIL-induced apoptosis, we used TRAIL-resistant human T cell leukemia virus type 1 (HTLV-1)-associated adult T cell leukemia/lymphoma (ATL) cells as a model system. So far, HTLV-1-associated ATL is incurable by presently known therapies. Here, we show that wogonin and the structurally related natural flavones apigenin and chrysin break TRAIL resistance in HTLV-1-associated ATL by transcriptional down-regulation of c-FLIP, a key inhibitor of death receptor signaling, and by up-regulation of TRAIL receptor 2 (TRAIL-R2). This effect is mediated through transcriptional inhibition of the p53 antagonist murine double minute 2 (Mdm2), leading to an increase in p53 levels and, consequently, to up-regulation of the p53 target gene TRAIL-R2. We also show that these flavones can sensitize to TNFα- and CD95-mediated cell death. Furthermore, we show that wogonin, apigenin, and chrysin also enhance TRAIL-mediated apoptosis in other human cancer cell lines including breast cancer cell line MDA-MB-231, colon cancer cell line HT-29, hepatocellular carcinoma cell line HepG2, melanoma cell line SK-MEL-37, and pancreatic carcinoma cell line Capan-1 by the same mechanism. Thus, our study suggests the potential use of these flavones as an adjuvant for TRAIL-mediated anticancer therapy.

Citing Articles

Modulating the p53-MDM2 pathway: the therapeutic potential of natural compounds in cancer treatment.

Ramli I, Cheriet T, Posadino A, Giordo R, Fenu G, Chukwuemeka Nwachukwu K EXCLI J. 2025; 23:1397-1439.

PMID: 39764218 PMC: 11701300. DOI: 10.17179/excli2024-7791.

TRAIL-Sensitizing Effects of Flavonoids in Cancer.

Luiz-Ferreira A, Pacifico T, Cruz A, Laudisi F, Monteleone G, Stolfi C Int J Mol Sci. 2023; 24(23).

PMID: 38068921 PMC: 10706592. DOI: 10.3390/ijms242316596.

Therapeutic Strategies for Pancreatic-Cancer-Related Type 2 Diabetes Centered around Natural Products.

Park M Int J Mol Sci. 2023; 24(21).

PMID: 37958889 PMC: 10648679. DOI: 10.3390/ijms242115906.

Apigenin improves cytotoxicity of antiretroviral drugs against HTLV-1 infected cells through the modulation of AhR signaling.

Sales D, Lin E, Stoffel V, Dickson S, Khan Z, Beld J NeuroImmune Pharm Ther. 2023; 2(1):49-62.

PMID: 37027342 PMC: 10070013. DOI: 10.1515/nipt-2022-0017.

Santin (5,7-Dihydroxy-3,6,4'-Trimetoxy-Flavone) Enhances TRAIL-Mediated Apoptosis in Colon Cancer Cells.

Klosek M, Jaworska D, Pietsz G, Szliszka E Life (Basel). 2023; 13(2).

PMID: 36836951 PMC: 9962120. DOI: 10.3390/life13020592.

References

Enoksson M, Robertson J, Gogvadze V, Bu P, Kropotov A, Zhivotovsky B . Caspase-2 permeabilizes the outer mitochondrial membrane and disrupts the binding of cytochrome c to anionic phospholipids. J Biol Chem. 2004; 279(48):49575-8. DOI: 10.1074/jbc.C400374200. View

Sun M, Zhang J, Liu S, Liu Y, Zheng D . Sp1 is involved in 8-chloro-adenosine-upregulated death receptor 5 expression in human hepatoma cells. Oncol Rep. 2007; 19(1):177-85. View

Baumbusch L, Myhre S, Langerod A, Bergamaschi A, Geisler S, Lonning P . Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. Mol Cancer. 2006; 5:47. PMC: 1636663. DOI: 10.1186/1476-4598-5-47. View

Fas S, Baumann S, Zhu J, Giaisi M, Treiber M, Mahlknecht U . Wogonin sensitizes resistant malignant cells to TNFalpha- and TRAIL-induced apoptosis. Blood. 2006; 108(12):3700-6. DOI: 10.1182/blood-2006-03-011973. View

Baumann S, Fas S, Giaisi M, Muller W, Merling A, Gulow K . Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCgamma1- and Ca2+-dependent apoptosis. Blood. 2007; 111(4):2354-63. DOI: 10.1182/blood-2007-06-096198. View

Itahana K, Mao H, Jin A, Itahana Y, Clegg H, Lindstrom M . Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell. 2007; 12(4):355-66. DOI: 10.1016/j.ccr.2007.09.007. View

Polier G, Ding J, Konkimalla B, Eick D, Ribeiro N, Kohler R . Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis. 2011; 2:e182. PMC: 3199715. DOI: 10.1038/cddis.2011.66. View

Miyoshi I, Kubonishi I, Yoshimoto S, Shiraishi Y . A T-cell line derived from normal human cord leukocytes by co-culturing with human leukemic T-cells. Gan. 1981; 72(6):978-81. View

Krammer P, Arnold R, Lavrik I . Life and death in peripheral T cells. Nat Rev Immunol. 2007; 7(7):532-42. DOI: 10.1038/nri2115. View

10.

Chang L, Kamata H, Solinas G, Luo J, Maeda S, Venuprasad K . The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell. 2006; 124(3):601-13. DOI: 10.1016/j.cell.2006.01.021. View

11.

Yoshida T, Maeda A, Tani N, Sakai T . Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett. 2001; 507(3):381-5. DOI: 10.1016/s0014-5793(01)02947-7. View

12.

Manfredi J . The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 2010; 24(15):1580-9. PMC: 2912554. DOI: 10.1101/gad.1941710. View

13.

Peng J, Qi Q, You Q, Hu R, Liu W, Feng F . Subchronic toxicity and plasma pharmacokinetic studies on wogonin, a natural flavonoid, in Beagle dogs. J Ethnopharmacol. 2009; 124(2):257-62. DOI: 10.1016/j.jep.2009.04.031. View

14.

Yamaguchi H, Wang H . CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem. 2004; 279(44):45495-502. DOI: 10.1074/jbc.M406933200. View

15.

Wuchter C, Krappmann D, Cai Z, Ruppert V, Scheidereit C, Dorken B . In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia. 2001; 15(6):921-8. DOI: 10.1038/sj.leu.2402131. View

16.

Qi Q, Peng J, Liu W, You Q, Yang Y, Lu N . Toxicological studies of wogonin in experimental animals. Phytother Res. 2008; 23(3):417-22. DOI: 10.1002/ptr.2645. View

17.

Osman F, Rowhani A . Real-time RT-PCR (TaqMan) assays for the detection of viruses associated with Rugose wood complex of grapevine. J Virol Methods. 2008; 154(1-2):69-75. DOI: 10.1016/j.jviromet.2008.09.005. View

18.

Wang S, Fischer P . Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci. 2008; 29(6):302-13. DOI: 10.1016/j.tips.2008.03.003. View

19.

Matsuoka M, Jeang K . Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007; 7(4):270-80. DOI: 10.1038/nrc2111. View

20.

Walczak H, Miller R, Ariail K, Gliniak B, Griffith T, Kubin M . Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999; 5(2):157-63. DOI: 10.1038/5517. View